





Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.4. Antihepatitis medicines](#) > [6.4.4.2. Medicines for hepatitis C](#) > [6.4.4.2.1. Medicines for hepatitis C](#) > [Pangenotypic direct-acting antiviral combinations](#)

EMLc

ATC codes: J05AP08

Indication	Chronic hepatitis C <span style="background-color: #0070C0; color: white; padding: 2px;">ICD11 code: 1E91.1</span>
INN	Sofosbuvir
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Pangenotypic when used in combination with daclatasvir or ravidasvir.
Formulations	Oral > Solid > tablet: 200 mg ; 400 mg
EML status history	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Pangenotypic direct-acting antiviral combinations
Therapeutic alternatives limitations for EMLc	Pangenotypic direct-acting antiviral combinations
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <a href="#">about patents.</a> 
Wikipedia	<a href="#">Sofosbuvir</a> 
DrugBank	<a href="#">Sofosbuvir</a> 

### Summary of evidence and Expert Committee recommendations

The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.

